A Randomized, Double-blind, Placebo-Controlled Multicenter Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 2 Different Intravenous Doses of TAK-671 for the Treatment of Coronavirus Disease 2019 in Adults
Latest Information Update: 09 Oct 2020
At a glance
- Drugs SB-26 (Primary)
- Indications COVID 2019 infections; Respiratory tract infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda
- 07 Oct 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Sep 2020 Planned End Date changed from 16 Oct 2020 to 30 Oct 2020.
- 14 Sep 2020 Planned primary completion date changed from 16 Oct 2020 to 30 Oct 2020.